217 related articles for article (PubMed ID: 11834608)
1. Phosphodiesterase isoenzyme families in human osteoarthritis chondrocytes--functional importance of phosphodiesterase 4.
Tenor H; Hedbom E; Häuselmann HJ; Schudt C; Hatzelmann A
Br J Pharmacol; 2002 Feb; 135(3):609-18. PubMed ID: 11834608
[TBL] [Abstract][Full Text] [Related]
2. Characterization of the cyclic nucleotide phosphodiesterase subtypes involved in the regulation of the L-type Ca2+ current in rat ventricular myocytes.
Verde I; Vandecasteele G; Lezoualc'h F; Fischmeister R
Br J Pharmacol; 1999 May; 127(1):65-74. PubMed ID: 10369457
[TBL] [Abstract][Full Text] [Related]
3. Inhibitory effects of flavonoids on phosphodiesterase isozymes from guinea pig and their structure-activity relationships.
Ko WC; Shih CM; Lai YH; Chen JH; Huang HL
Biochem Pharmacol; 2004 Nov; 68(10):2087-94. PubMed ID: 15476679
[TBL] [Abstract][Full Text] [Related]
4. Rapid regulation of PDE-2 and PDE-4 cyclic AMP phosphodiesterase activity following ligation of the T cell antigen receptor on thymocytes: analysis using the selective inhibitors erythro-9-(2-hydroxy-3-nonyl)-adenine (EHNA) and rolipram.
Michie AM; Lobban M; Müller T; Harnett MM; Houslay MD
Cell Signal; 1996 Feb; 8(2):97-110. PubMed ID: 8730511
[TBL] [Abstract][Full Text] [Related]
5. Phosphodiesterase type 4 expression and anti-proliferative effects in human pulmonary artery smooth muscle cells.
Growcott EJ; Spink KG; Ren X; Afzal S; Banner KH; Wharton J
Respir Res; 2006 Jan; 7(1):9. PubMed ID: 16423283
[TBL] [Abstract][Full Text] [Related]
6. Challenge of human Jurkat T-cells with the adenylate cyclase activator forskolin elicits major changes in cAMP phosphodiesterase (PDE) expression by up-regulating PDE3 and inducing PDE4D1 and PDE4D2 splice variants as well as down-regulating a novel PDE4A splice variant.
Erdogan S; Houslay MD
Biochem J; 1997 Jan; 321 ( Pt 1)(Pt 1):165-75. PubMed ID: 9003416
[TBL] [Abstract][Full Text] [Related]
7. Phosphodiesterase profile of human B lymphocytes from normal and atopic donors and the effects of PDE inhibition on B cell proliferation.
Gantner F; Götz C; Gekeler V; Schudt C; Wendel A; Hatzelmann A
Br J Pharmacol; 1998 Mar; 123(6):1031-8. PubMed ID: 9559883
[TBL] [Abstract][Full Text] [Related]
8. Phosphodiesterase inhibitors in airways disease.
Fan Chung K
Eur J Pharmacol; 2006 Mar; 533(1-3):110-7. PubMed ID: 16458289
[TBL] [Abstract][Full Text] [Related]
9. In vitro differentiation of human monocytes to macrophages: change of PDE profile and its relationship to suppression of tumour necrosis factor-alpha release by PDE inhibitors.
Gantner F; Kupferschmidt R; Schudt C; Wendel A; Hatzelmann A
Br J Pharmacol; 1997 May; 121(2):221-31. PubMed ID: 9154331
[TBL] [Abstract][Full Text] [Related]
10. Assessing the emetic potential of PDE4 inhibitors in rats.
Robichaud A; Savoie C; Stamatiou PB; Lachance N; Jolicoeur P; Rasori R; Chan CC
Br J Pharmacol; 2002 Jan; 135(1):113-8. PubMed ID: 11786486
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of PDE3B augments PDE4 inhibitor-induced apoptosis in a subset of patients with chronic lymphocytic leukemia.
Moon E; Lee R; Near R; Weintraub L; Wolda S; Lerner A
Clin Cancer Res; 2002 Feb; 8(2):589-95. PubMed ID: 11839681
[TBL] [Abstract][Full Text] [Related]
12. The role of phosphodiesterase isoforms 2, 5, and 9 in the regulation of NO-dependent and NO-independent cGMP production in the rat cervical spinal cord.
de Vente J; Markerink-van Ittersum M; Vles JS
J Chem Neuroanat; 2006 Jun; 31(4):275-303. PubMed ID: 16621445
[TBL] [Abstract][Full Text] [Related]
13. Dexamethasone down-regulates cAMP-phosphodiesterase in human osteosarcoma cells.
Ahlström M; Pekkinen M; Huttunen M; Lamberg-Allardt C
Biochem Pharmacol; 2005 Jan; 69(2):267-75. PubMed ID: 15627479
[TBL] [Abstract][Full Text] [Related]
14. Prostaglandin E2-mediated anabolic effect of a novel inhibitor of phosphodiesterase 4, XT-611, in the in vitro bone marrow culture.
Miyamoto K; Suzuki H; Yamamoto S; Saitoh Y; Ochiai E; Moritani S; Yokogawa K; Waki Y; Kasugai S; Sawanishi H; Yamagami H
J Bone Miner Res; 2003 Aug; 18(8):1471-7. PubMed ID: 12929936
[TBL] [Abstract][Full Text] [Related]
15. Profiling of functional phosphodiesterase in mesangial cells using a CRE-SEAP-based reporting system.
Zhu Y; Yao J; Meng Y; Kasai A; Hiramatsu N; Hayakawa K; Miida T; Takeda M; Okada M; Kitamura M
Br J Pharmacol; 2006 Jul; 148(6):833-44. PubMed ID: 16751794
[TBL] [Abstract][Full Text] [Related]
16. The effect of selective and non-selective phosphodiesterase inhibitors on allergen- and leukotriene C(4)-induced contractions in passively sensitized human airways.
Schmidt DT; Watson N; Dent G; Rühlmann E; Branscheid D; Magnussen H; Rabe KF
Br J Pharmacol; 2000 Dec; 131(8):1607-18. PubMed ID: 11139438
[TBL] [Abstract][Full Text] [Related]
17. Interleukin-1beta induces phosphodiesterase 4B2 expression in human myometrial cells through a prostaglandin E2- and cyclic adenosine 3',5'-monophosphate-dependent pathway.
Oger S; Méhats C; Dallot E; Ferré F; Leroy MJ
J Clin Endocrinol Metab; 2002 Dec; 87(12):5524-31. PubMed ID: 12466348
[TBL] [Abstract][Full Text] [Related]
18. Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro.
Hatzelmann A; Schudt C
J Pharmacol Exp Ther; 2001 Apr; 297(1):267-79. PubMed ID: 11259554
[TBL] [Abstract][Full Text] [Related]
19. Cyclic nucleotide phosphodiesterases (PDEs) in human osteoblastic cells; the effect of PDE inhibition on cAMP accumulation.
Ahlström M; Pekkinen M; Huttunen M; Lamberg-Allardt C
Cell Mol Biol Lett; 2005; 10(2):305-19. PubMed ID: 16010295
[TBL] [Abstract][Full Text] [Related]
20. Characterization of phosphodiesterase 4 in guinea-pig macrophages: multiple activities, association states and sensitivity to selective inhibitors.
Kelly JJ; Barnes PJ; Giembycz MA
Br J Pharmacol; 1998 May; 124(1):129-40. PubMed ID: 9630352
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
